Immunic, Inc. (IMUX)
| Market Cap | 140.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -97.17M |
| Shares Out | 13.05M |
| EPS (ttm) | -6.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 375,262 |
| Open | 9.58 |
| Previous Close | 9.98 |
| Day's Range | 9.58 - 10.91 |
| 52-Week Range | 5.06 - 15.10 |
| Beta | 1.37 |
| Analysts | Strong Buy |
| Price Target | 45.00 (+318.61%) |
| Earnings Date | May 14, 2026 |
About IMUX
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patien... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for IMUX stock is "Strong Buy." The 12-month stock price target is $45.0, which is an increase of 318.61% from the latest price.
News
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.
– Proven Leader in Neurology Drug Development, Including for Several Approved MultipleSclerosis Therapies – – Strong Experience in Advancing Late-Stage Clinical Programs and Obtaining Global Regulator...
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
NEW YORK, April 23, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or ...
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
Stifel on Thursday initiated coverage on Immunic Inc. (NASDAQ: IMUX), a late-stage biotechnology company developing oral therapies for neurologic and gastrointestinal diseases.
Immunic to Participate in Scientific and Medical Conferences in April
NEW YORK, April 9, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced p...
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced t...
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis – – Served on Original Team Responsible for the Launch of Copaxone® in the Unit...
Immunic Transcript: Stifel 2026 Virtual CNS Forum
2026 is set to be pivotal with phase III RMS data and NDA submission preparations. Vidofludimus calcium offers a unique safety and neuroprotective profile, targeting both relapsing and progressive MS, with strong clinical data and significant commercial potential.
Immunic Transcript: Leerink Global Healthcare Conference 2026
Vidofludimus Calcium offers a unique dual mechanism for MS, showing strong efficacy and safety in phase II trials. Phase III studies in relapsing MS are fully enrolled and expected to read out by year-end, while a pivotal PPMS trial is set to launch, targeting a multi-billion-dollar market opportunity.
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 – – Broad Protection Extends to All Forms of Vidofludimus, In...
Immunic to Participate in Investor Conferences in March
NEW YORK, March 3, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal disease...
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million in a Private Placement, with Potential ...
Immunic Announces Closing of Oversubscribed Private Placement Financing
– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiat...
Immunic Stock Jumps After Pricing $400 Million Private Placement
Immunic Inc (NASDAQ: IMUX) is surging Friday after the late‑stage biotech announced a private placement of up to $400 million.
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiat...
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity – – CALLIPER Subset Data Demonstrate Reductions in EBV-Specific T-Cell Re...
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 – – Phase 2 CALLIPER Data Showed Vidofludimus Calci...
Immunic Transcript: Evercore ISI 8th Annual HealthCONx Conference
Upcoming Phase 3 data in relapsing MS and strong Phase 2 results in progressive MS highlight a pivotal year ahead. The therapy's unique neuroprotective mechanism and favorable safety profile position it to compete strongly in the oral MS market, with significant financial and partnership flexibility.
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseas...
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41st Congress of ECTRIMS – – Phase 2 CALLIPER Data Demonstrated Statistically Significant 24-We...
Immunic to Participate in Industry and Investor Conferences in November
NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...
Immunic to Participate in Scientific and Investor Conferences in October
NEW YORK , Oct. 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory...
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over ...
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
– Fifth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis – – Comprehensive Intellectual Property Strategy Secures Protection Into 2041 in the U.S., Unless Extended Further – N...
Immunic Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Vidofludimus calcium, a dual-mechanism oral therapy, shows robust efficacy and safety in both relapsing and progressive MS, with significant reductions in disability and strong biomarker support. Phase III trials are fully enrolled, with top-line data expected in late 2026.
Immunic to Participate in Investor and Scientific Conferences in September
NEW YORK , Sept. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory...